UK markets close in 1 hour 21 minutes
  • FTSE 100

    6,879.94
    -9.18 (-0.13%)
     
  • FTSE 250

    22,210.41
    +56.86 (+0.26%)
     
  • AIM

    1,241.60
    +6.91 (+0.56%)
     
  • GBP/EUR

    1.1507
    -0.0024 (-0.21%)
     
  • GBP/USD

    1.3741
    -0.0002 (-0.01%)
     
  • BTC-GBP

    45,618.99
    +1,364.09 (+3.08%)
     
  • CMC Crypto 200

    1,337.07
    +43.08 (+3.33%)
     
  • S&P 500

    4,133.06
    +5.07 (+0.12%)
     
  • DOW

    33,619.78
    -125.62 (-0.37%)
     
  • CRUDE OIL

    60.23
    +0.53 (+0.89%)
     
  • GOLD FUTURES

    1,748.60
    +15.90 (+0.92%)
     
  • NIKKEI 225

    29,751.61
    +212.88 (+0.72%)
     
  • HANG SENG

    28,497.25
    +43.97 (+0.15%)
     
  • DAX

    15,247.25
    +32.25 (+0.21%)
     
  • CAC 40

    6,172.71
    +11.03 (+0.18%)
     

Karolinska Development Annual Report 2020 published

  • Oops!
    Something went wrong.
    Please try again later.
Karolinska Development AB (publ)
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

STOCKHOLM, SWEDEN – March 25, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2020.

The report is now available to download at www.karolinskadevelopment.com

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Per Aniansson, CFO, Karolinska Development AB
Phone: +46 70 866 04 29, e-mail: per.aniansson@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

Attachment